Use of Oral Corticosteroids and Risk of Fractures
By T. V. Staa, H. Leufkens, L. Abenhaim, B. Zhang, Chris Cooper. Journal of Bone and Mineral Research, 2005
639 citations recorded by the source corpus.
Subfields: Orthopedics and Sports Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/f943b28670bcf8185ee3918a54cb397a1b702799
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Orthopedics and Sports Medicine
- J. Kanis
- Chris Cooper
- J. Reginster
- Eugene V. McCloskey
- H. Johansson
- R. Rizzoli
- O. Johnell
- on behalf of the International Osteoporosis Foundation
Citations in the corpus
- UK clinical guideline for the prevention and treatment of osteoporosis (2017, background): “increase with the dose and duration of therapy [121, 122].”
- Assessment of fracture risk (2005, background): “Glucocorticoids are an important cause of osteoporosis and fractures [42,43].”
- Glucocorticoid-induced osteoporosis (2015, positive): “The increase in fracture risk is immediate, as early as 3 months after the initiation of therapy and reverses sharply after discontinuation of GCs. 45 This cannot be explained by BMD changes, but can be related to the added effects of GCs on bone remodelling previously uncoupled by the in fl…”
- Long-term proton pump inhibitor therapy and risk of hip fracture. (2006, background): “The 1-year duration was chosen because alterations in fracture risk due to the use of other medications, such as bisphosphonates, thiazide diuretics, and corticosteroids were apparent after 1 year of exposure.(25,26) Calcium absorption decreases with age while urinary calcium excretion increases.”
- Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids (2005, background): “[206] Glucocorticoids act on coid dose[220] and correlates better with the daily various levels of transplant rejection.”
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, background): “Dose responses are also evident for glucocorticoid exposure [81], cigarette smoking [82] and alcohol intake [62].”
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “Doseresponses are also evident for glucocorticoid exposure [93], cigarette smoking [61] and alcohol intake [60].”
- Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. (2004, background): “In support of this idea, in humans treated with glucocorticoids, the rate of fracture increases within 3 months of the initiation of therapy, even before significant loss of BMD (25, 26).”
- Disorders of bone remodeling. (2011, background): “Bone loss occurs within the first several months of initiating GC treatment, and prolonged GC-based therapy leads to a significant decrease in bone mass and an increased risk of fracture (112).”